{
     "PMID": "24240639",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20141021",
     "LR": "20140127",
     "IS": "1875-8908 (Electronic) 1387-2877 (Linking)",
     "VI": "39",
     "IP": "2",
     "DP": "2014",
     "TI": "Identification of N-terminally truncated pyroglutamate amyloid-beta in cholesterol-enriched diet-fed rabbit and AD brain.",
     "PG": "441-55",
     "LID": "10.3233/JAD-130590 [doi]",
     "AB": "The main amyloid-beta peptide (Abeta) variants detected in the human brain are Abeta1-40 and Abeta1-42; however, a significant proportion of Abeta in Alzheimer's disease (AD) brain also consists of N-terminal truncated/modified species. AbetaN3(pE), Abeta peptide bearing amino-terminal pyroglutamate at position 3, has been demonstrated to be a major N-truncated/modified constituent of intracellular, extracellular, and vascular Abeta deposits in AD and Down syndrome brain tissue. It has been previously demonstrated that rabbits fed a diet enriched in cholesterol and given water containing trace copper levels developed AD-like pathology including intraneuronal and extracellular Abeta accumulation, tau hyperphosphorylation, vascular inflammation, astrocytosis, microgliosis, reduced levels of acetylcholine, as well as learning deficits and thus, may be used as a non-transgenic animal model of sporadic AD. In the present study, we have demonstrated for the first time the presence of AbetaN3(pE) in blood vessels in cholesterol-enriched diet-fed rabbit brain. In addition, we detected AbetaN3(pE) immunoreactivity in all postmortem AD brain samples studied. We believe that our results are potentially important for evaluation of novel therapeutic molecules/strategies targeting Abeta peptides in a suitable non-transgenic animal model.",
     "FAU": [
          "Perez-Garmendia, Roxanna",
          "Hernandez-Zimbron, Luis Fernando",
          "Morales, Miguel Angel",
          "Luna-Munoz, Jose",
          "Mena, Raul",
          "Nava-Catorce, Miriam",
          "Acero, Gonzalo",
          "Vasilevko, Vitaly",
          "Viramontes-Pintos, Amparo",
          "Cribbs, David H",
          "Gevorkian, Goar"
     ],
     "AU": [
          "Perez-Garmendia R",
          "Hernandez-Zimbron LF",
          "Morales MA",
          "Luna-Munoz J",
          "Mena R",
          "Nava-Catorce M",
          "Acero G",
          "Vasilevko V",
          "Viramontes-Pintos A",
          "Cribbs DH",
          "Gevorkian G"
     ],
     "AD": "Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico (UNAM), Cuidad Universitaria, Mexico, DF, Mexico. Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico (UNAM), Cuidad Universitaria, Mexico, DF, Mexico. Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico (UNAM), Cuidad Universitaria, Mexico, DF, Mexico. Brain Bank, National Laboratory of Experimental Services, CINVESTAV-IPN, Mexico, DF, Mexico. Department of Neurosciences, CINVESTAV-IPN, Mexico, DF, Mexico. Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico (UNAM), Cuidad Universitaria, Mexico, DF, Mexico. Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico (UNAM), Cuidad Universitaria, Mexico, DF, Mexico. Institute for Memory Impairments and Neurological Disorders, University of California Irvine, Irvine, CA, USA. Brain Bank, National Laboratory of Experimental Services, CINVESTAV-IPN, Mexico, DF, Mexico. Institute for Memory Impairments and Neurological Disorders, University of California Irvine, Irvine, CA, USA Department of Neurology, University of California Irvine, Irvine, CA, USA. Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico (UNAM), Cuidad Universitaria, Mexico, DF, Mexico.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "PL": "Netherlands",
     "TA": "J Alzheimers Dis",
     "JT": "Journal of Alzheimer's disease : JAD",
     "JID": "9814863",
     "RN": [
          "0 (A N11(pE) peptide)",
          "0 (A N3(pE) peptide)",
          "0 (Amyloid beta-Peptides)",
          "0 (Antibodies)",
          "0 (Cholesterol, Dietary)",
          "0 (Peptide Fragments)",
          "0 (amyloid beta-protein (1-42))"
     ],
     "SB": "IM",
     "MH": [
          "Aged",
          "Aged, 80 and over",
          "Alzheimer Disease/*metabolism",
          "Amyloid beta-Peptides/*metabolism",
          "Animals",
          "Antibodies/metabolism",
          "Astrocytes/metabolism",
          "Brain/*blood supply/*metabolism",
          "Cerebral Cortex/blood supply/metabolism",
          "Cholesterol, Dietary/*administration & dosage",
          "Extracellular Space/metabolism",
          "Hippocampus/blood supply/metabolism",
          "Humans",
          "Intracellular Space/metabolism",
          "Male",
          "Mice",
          "Mice, Transgenic",
          "Neurons/metabolism",
          "Peptide Fragments/metabolism",
          "Rabbits"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "Alzheimer's disease",
          "amyloid-beta",
          "animal model",
          "cholesterol-fed rabbit",
          "pyroglutamate-modified amyloid"
     ],
     "EDAT": "2013/11/19 06:00",
     "MHDA": "2014/10/22 06:00",
     "CRDT": [
          "2013/11/19 06:00"
     ],
     "PHST": [
          "2013/11/19 06:00 [entrez]",
          "2013/11/19 06:00 [pubmed]",
          "2014/10/22 06:00 [medline]"
     ],
     "AID": [
          "Q10165170833076P [pii]",
          "10.3233/JAD-130590 [doi]"
     ],
     "PST": "ppublish",
     "SO": "J Alzheimers Dis. 2014;39(2):441-55. doi: 10.3233/JAD-130590.",
     "term": "hippocampus"
}